COVID-19住院后静脉血栓栓塞症:COVID静脉血栓虚拟监测研究
VVIRTUOSO研究为前瞻性多中心队列研究,2021至2022年在加拿大6个中心纳入513例因实验室确诊COVID-19住院或住院期间确诊的患者,出院后90天虚拟随访。90天症状性静脉血栓栓塞症累积发生率为0.90%(95%CI 0.30%-2.18%),作者认为常规出院后药物血栓预防对未经选择的患者可能不提供净临床获益。
要点
- COVID-19住院后90天症状性VTE累积发生率为0.90%(95%CI 0.30%-2.18%)
- 大出血累积发生率0.20%,临床相关非大出血1.47%,死亡率3.19%
- 作者认为常规出院后药物血栓预防对未经选择患者可能无净临床获益
核心结论
- COVID-19住院后症状性VTE发生率低,作者认为常规出院后药物血栓预防对未经选择的患者可能不提供净临床获益。
研究设计与样本
- VVIRTUOSO研究为前瞻性多中心队列研究,2021至2022年在加拿大6个中心开展。
- 纳入≥18岁因实验室确诊COVID-19住院或住院期间确诊且在出院1周内的患者,共513例入组,411例完成90天随访。
- 出院后通过电话或视频进行90天虚拟随访,主要结局为90天症状性、客观确认的急性VTE。
主要发现
- 平均年龄58岁,女性占46%。
- 90天症状性VTE累积发生率为0.90%(95%CI 0.30%-2.18%)。
- 大出血累积发生率为0.20%(95%CI 0.02-1.10),临床相关非大出血为1.47%(95%CI 0.66-2.90),死亡率为3.19%(95%CI 1.86-5.08)。
临床怎么用
- 作者认为,对于未经选择的COVID-19住院后患者,常规出院后药物血栓预防可能不提供净临床获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 induces a prothrombotic state that increases the risk of venous thromboembolism (VTE) in hospitalized patients, but the incidence of postdischarge VTE is not well characterized in prospective studies. OBJECTIVE: To determine the incidence of symptomatic VTE after hospitalization with COVID-19 infection. METHODS: The Venous Thrombosis Virtual Surveillance in COVID (VVIRTUOSO) study was a prospective multicenter cohort study (2021 to 2022) conducted at 6 sites in Canada. Patients ≥18 years, hospitalized for laboratory-confirmed COVID-19 or diagnosed during hospitalization within 1 week of hospital discharge, were included and followed virtually for 90 days (telephone or video). Exclusion criteria included unconfirmed diagnosis of COVID-19, no access to a telephone, computer, or tablet for virtual assessment, therapeutic-dose anticoagulation after hospital discharge, or patients (or their delegate) unable or unwilling to provide informed consent. The primary outcome was symptomatic, objectively confirmed acute VTE at 90 days. Secondary outcomes included 30-day incidence of symptomatic VTE, major bleeding, clinically relevant non-major bleeding, and mortality. RESULTS: A total of 513 participants were enrolled, and 411 participants completed 90-day follow-up. Mean age was 58 years and 46% were females. At 90 days, the cumulative incidence of symptomatic VTE was 0.90% (95% CI, 0.30%-2.18%). The cumulative incidence of major bleeding was 0.20% (95% CI, 0.02-1.10), clinically relevant non-major bleeding was 1.47% (95% CI, 0.66-2.90), and mortality was 3.19% (95% CI, 1.86-5.08). CONCLUSION: The incidence of symptomatic VTE after hospitalization with COVID-19 infection is low. Our findings suggest that routine postdischarge pharmacological thromboprophylaxis may not offer net clinical benefit for unselected patients.
引用
- Siegal DM, Arsenault MP, Abdulrehman J, et al. Venous thromboembolism after hospitalization for COVID-19: venous thrombosis virtual surveillance in COVID study. J Thromb Haemost. 2025. PMID: 40288681. doi:10.1016/j.jtha.2025.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。